Liminatus Pharma closes merger with InnocsAI; issues 11.2M common shares and 158.9K Series A preferred

Liminatus Pharma, Inc.

Merger closed July 2, 2026; Liminatus acquired InnocsAI, a CAR-T therapy company.
Issued 11,188,729 common shares and 158,881.1271 Series A Preferred shares (each convertible into 10,000 common shares).
Total consideration 1.6B shares at $0.20/share, but capped at 19.99% of pre-closing outstanding common stock.
Series A Preferred non-voting, convertible only after stockholder approval; meeting to be held.
Registration rights and non-compete agreements executed with InnocsAI members and key employees.

item 1.01 item 2.01 item 3.02 item 5.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.